https://www.has-sante.fr/jcms/p_3427323/fr/lupkynis-voclosporine-glomerulonephrite-lupique 2023 false false false France adult administration, oral treatment outcome insurance, health, reimbursement drug therapy, combination Calcineurin Inhibitors voclosporin evaluation of the transparency committee lupkynis voclosporin lupus nephritis
--- Lupkynis - voclosporin https://www.ema.europa.eu/en/medicines/human/EPAR/lupkynis 2022 false false false Netherlands French English treatment outcome syndication feed summary of product characteristics package leaflet drug evaluation voclosporin voclosporin Product containing precisely voclosporin 7.9 milligram/1 each conventional release
oral capsule (clinical drug) administration, oral drug approval europe lupus nephritis drug therapy, combination mycophenolate mofetil adult Systemic Lupus Erythematosus Nephritis Class III Systemic Lupus Erythematosus Nephritis Class IV Systemic Lupus Erythematosus Nephritis Class V Calcineurin Inhibitors Calcineurin Inhibitors product surveillance, postmarketing drug interactions pregnancy breast feeding drug evaluation, preclinical